Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Biogen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a framework for the regulation of therapeutic goods in Australia, ensuring that they meet safety, quality, and efficacy standards. The Act was introduced to address the need for a comprehensive regulatory system to oversee the supply, advertising, and evaluation of therapeutic goods, including medicines, medical devices, and blood products. This legislation is overseen by the Australian Parliament and its policy objective is to protect public health by ensuring that therapeutic goods available in the market are safe, of high quality, and perform as claimed. In specific instances, such as the consent granted for the importation and supply of Fampridine (FAMPYRA) 10 mg modified release tablets, the Act allows for flexibility to accommodate certain circumstances that may not fully meet regulatory requirements, provided that public health and safety are not compromised. In this particular case, the Therapeutic Goods Administration, acting on behalf of the Department of Health, issued a consent under sections 14 and 14A of the Act to allow the importation and supply of Fampridine tablets with carton labels that do not conform to specific labelling requirements. This consent was granted to Biogen Australia Pty Ltd and is effective from 11 December 2015 until the nominated batches are exhausted or expired. The consent is subject to conditions that ensure the carton labels are those currently approved for use, thereby maintaining the integrity of the therapeutic goods regulation while allowing for specific exceptions that benefit public health.

Scope and Application

The Therapeutic Goods Act 1989, under sections 14 and 14A, governs the regulation of therapeutic goods in Australia, including the import and supply of medicinal products. In this specific instance, a delegate of the Secretary of the Department of Health granted Biogen Australia Pty Ltd consent to import and supply Fampridine (FAMPYRA) 10 mg modified release tablets, which do not conform to certain labelling requirements stipulated in the Therapeutic Goods Order No. 69. This consent applies to the particular batches of Fampridine products listed, which are identified by their Australian Register of Therapeutic Goods (AUST R) number and batch numbers. The consent is effective from 11 December 2015 until the specified batches are exhausted or expired. The consent is also subject to conditions ensuring that the carton labels used are those currently approved for use. The Act applies to entities such as Biogen Australia Pty Ltd, which are involved in the importation and supply of therapeutic goods, ensuring compliance with regulatory standards set forth by the Therapeutic Goods Administration.

Key Provisions

The Therapeutic Goods Act 1989, particularly sections 14 and 14A, provide a framework for the regulation of therapeutic goods, including medicines, in Australia. Section 14 allows for the consent to import and supply therapeutic goods that do not fully comply with the Australian Therapeutic Goods Regulations, while Section 14A specifies the conditions under which such consent can be granted. In this specific case, a delegate of the Secretary of the Department of Health has granted consent to Biogen Australia Pty Ltd for the importation and supply of Fampridine (FAMPYRA) 10 mg modified release tablets, specifically batch numbers 77505, 77519, 7647, and 7782, which do not conform to the label requirements outlined in paragraph 3(2)(l) of Therapeutic Goods Order No. 69. This consent allows the supply of these products with carton labels that include the sponsor's old address and/or name. Under the Therapeutic Goods Act, the obligations placed on parties such as Biogen Australia Pty Ltd involve adhering to the conditions set forth in the consent granted by the delegate of the Secretary of the Department of Health. Specifically, they must ensure that the carton labels used for the distribution of the Fampridine (FAMPYRA) 10 mg modified release tablets are the ones approved for current use. This means that despite the non-conformity with the label requirements, the products can still be supplied as long as the approved labels are utilised. Additionally, the consent is time-bound, effective from 11 December 2015 until the nominated batches are exhausted or have expired. Failure to comply with the conditions stipulated in the consent granted under the Therapeutic Goods Act could lead to various consequences. Although the Act does not explicitly state the penalties for breach in this context, breaches of therapeutic goods regulations generally could result in enforcement actions. These actions may include fines, product recalls, or legal proceedings. The Therapeutic Goods (Enforcement) Regulations 1991 provide further detail on penalties, including substantial financial penalties and potential criminal charges for serious or repeated breaches. Therefore, it is crucial for Biogen Australia Pty Ltd to strictly adhere to the terms of the consent to avoid any legal repercussions.